PharmAla Biotech Holdings, Inc.

As of May 31, 2026, PharmAla Biotech Holdings Inc. carries a market capitalization of 12.84M, placing it among publicly traded companies globally. Its enterprise value stands at 12.66M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of May 31, 2026, PharmAla Biotech Holdings Inc. has 109.22M shares outstanding.

These figures are as of May 31, 2026. The price-to-sales ratio is 13.83, and the price-to-book ratio stands at 9.08.

These figures are as of May 31, 2026. The EV/Sales ratio of 13.78 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 12.66M versus a market cap of 12.84M, with the gap driven by net debt and cash on the balance sheet.

As of May 31, 2026, PharmAla Biotech Holdings Inc. maintains a current ratio of 1.17, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended May 31, 2026, PharmAla Biotech Holdings Inc. posted a negative return on equity (ROE) of -68.36, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -48.00, reflecting losses generated across the asset base. The company generates approximately 459,520.05 in revenue per employee across its workforce of 2.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.54 indicates how many times PharmAla Biotech Holdings Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, PharmAla Biotech Holdings Inc.'s stock has gained approximately 51.67% over the past 52 weeks. The 50-day moving average sits at 0.16, while the 200-day moving average is 0.11.

Over the twelve months ended May 31, 2026, PharmAla Biotech Holdings Inc. generated 919,040.09 in revenue and converted that into -1.17M in net income, yielding earnings per share of -0.01. EBITDA reached -1.12M, while operating income came in at -1.15M.

These figures are as of May 31, 2026. Total book value stands at 1.41M, with working capital of 139,942.72 providing operational flexibility.

PharmAla Biotech Holdings Inc. produced -702,187.34 in operating cash flow over the twelve months ended May 31, 2026. After subtracting -41,707.39 in capital expenditures, free cash flow totaled -743,894.73 - equivalent to -0.01 per share.

Over the twelve months ended May 31, 2026, PharmAla Biotech Holdings Inc. posted a gross margin of 79.02, reflecting its pricing power and cost economics. The operating margin of -125.33 and net profit margin of -126.87 provide insight into operational efficiency.

These figures cover the twelve months ended May 31, 2026. Free cash flow yield is negative at -5.85: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.04, meaning PharmAla Biotech Holdings Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of May 31, 2026, PharmAla Biotech Holdings Inc. has an Altman Z-Score of -2.10, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.